Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to "Buy" by StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was upgraded by equities researchers at StockNews.com from a "hold" rating to a "buy" rating in a note issued to investors on Monday.

Several other equities analysts have also issued reports on ALNY. William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Citigroup dropped their price objective on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a "buy" rating on the stock in a research note on Friday, February 16th. Wolfe Research began coverage on Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They issued a "peer perform" rating on the stock. Chardan Capital dropped their price objective on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a "buy" rating on the stock in a research note on Friday, February 16th. Finally, The Goldman Sachs Group downgraded Alnylam Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $230.00 to $173.00 in a research note on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $215.88.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $4.05 during midday trading on Monday, reaching $147.36. 439,847 shares of the company were exchanged, compared to its average volume of 772,379. The company's fifty day moving average price is $150.21 and its 200 day moving average price is $165.76. The company has a market cap of $18.56 billion, a price-to-earnings ratio of -41.17 and a beta of 0.39. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.10. The business had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. The business's revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the company earned ($1.68) earnings per share. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -4.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Harbor Capital Advisors Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 1.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company's stock worth $562,000 after purchasing an additional 51 shares during the period. EP Wealth Advisors LLC increased its holdings in shares of Alnylam Pharmaceuticals by 6.4% in the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company's stock worth $208,000 after purchasing an additional 71 shares during the period. Commerce Bank increased its holdings in shares of Alnylam Pharmaceuticals by 1.7% in the fourth quarter. Commerce Bank now owns 4,683 shares of the biopharmaceutical company's stock worth $896,000 after purchasing an additional 77 shares during the period. Envestnet Portfolio Solutions Inc. increased its stake in Alnylam Pharmaceuticals by 7.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 1,368 shares of the biopharmaceutical company's stock valued at $262,000 after acquiring an additional 89 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its stake in Alnylam Pharmaceuticals by 2.1% in the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company's stock valued at $800,000 after acquiring an additional 93 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.